ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Effects of romosozumab on the peripheral and axial skeleton in postmenopausal women at high fracture risk: real-world evidence from DXA and HR-pQCT data.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence on the effects of romosozumab mainly concerns axial aBMD. In 28 postmenopausal women, we found that spine and hip aBMD (DXA) significantly increased, while volumetric BMD, microarchitecture, and strength at the radius and tibia (HR-pQCT) remained unchanged or deteriorated. Most HR-pQCT changes did not differ from those in age-matched women on bisphosphonate treatment. PURPOSE: We assessed the effects of ROMO treatment on the axial skeleton using dual-energy X-ray absorptiometry (DXA) and on the peripheral skeleton using high-resolution peripheral quantitative CT (HR-pQCT) in real-world data of postmenopausal women at high fracture risk and compared HR-pQCT changes with those during bisphosphonate (BP) treatment.
methodsAs part of regular care in our hospital, DXA (lumbar spine, hip) and HR-pQCT (distal radius, distal tibia) were performed before the start (T0) and after 12 months (T1) of ROMO treatment. HR-pQCT results were compared with those in 55 age-matched women receiving BP treatment after a recent fracture.
resultsROMO data were available of 28 women (72.4 ± 7.6 years, 67.9% treatment-naïve). At T0, areal bone mineral density (aBMD) T-scores were -2.3 ± 1.6 (lumbar spine), -2.1 ± 0.7 (total hip), and -2.7 ± 0.5 (femoral neck). At T1, aBMD was significantly higher than at T0 at the lumbar spine (+9.6% [IQR = 6.6,15.7], p < 0.001) and total hip (+4.4 ± 5.8%, p = 0.001) but not femoral neck. At the distal radius, a significant decrease was found in total (-2.4%, [-4.3,-0.1], p = 0.004) and trabecular (-1.7%, [-3.5,0.5], p = 0.013) volumetric BMD and in trabecular number, cortical thickness, and cortical area. Trabecular area and separation significantly increased. At the distal tibia, a significant change was found in trabecular number (decrease) and in trabecular thickness, separation, and heterogeneity (increase). Changes in radial and tibial stiffness and failure load were not significant. Most HR-pQCT changes did not significantly differ from those in the BP cohort.
conclusionAfter 12 months of ROMO treatment, aBMD increased significantly at the lumbar spine and total hip, while volumetric BMD, microarchitecture, and strength at the peripheral skeleton did not change or deteriorated.
Indexed as
Identifiers
42711379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.